Related Experiment Video
Updated: Jun 28, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Changes in serum potassium mediate thiazide-induced diabetes
Tariq Shafi1, Lawrence J Appel, Edgar R Miller
1Division of Nephrology, Johns Hopkins University School of Medicine, Baltimore, MD 21224-2780, USA. tshafi@jhmi.edu
Hypertension (Dallas, Tex. : 1979)
|November 5, 2008
Summary
Thiazide blood pressure medications increase diabetes risk early in treatment, primarily by lowering serum potassium. Potassium levels mediate this risk, suggesting supplementation could prevent thiazide-induced diabetes.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Clinical Pharmacology
Background:
- Thiazide diuretics are first-line treatments for hypertension.
- Thiazides are known to increase the risk of developing diabetes.
- A potential mechanism involves thiazide-induced hypokalemia (low serum potassium).
Purpose of the Study:
- To investigate whether changes in serum potassium mediate the increased risk of diabetes associated with thiazide use.
- To analyze the temporal relationship between thiazide treatment, potassium levels, and incident diabetes.
Main Methods:
- Analysis of data from 3790 nondiabetic participants in the Systolic Hypertension in Elderly Program (SHEP) trial.
- Participants aged >or=60 years received chlorthalidone (a thiazide) or placebo.
- Incident diabetes defined by specific glucose criteria or medication use; serum potassium changes measured in year 1.
Main Results:
- Chlorthalidone use significantly increased diabetes risk (HR: 2.07) in year 1.
- Adjusting for serum potassium changes reduced this risk (HR: 1.54), indicating mediation (41% attenuation).
- A 0.5-mEq/L decrease in serum potassium independently raised diabetes risk by 45%.
Conclusions:
- Thiazide-induced diabetes develops early in treatment and is significantly mediated by serum potassium reduction.
- Potassium supplementation may be a strategy to prevent thiazide-associated diabetes.
- Further randomized trials are warranted to test this hypothesis.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:29Diabetes Insipidus I: Introduction
Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...
01:22Diabetes Insipidus II: Pathophysiology
Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Type I Diabetes III: Clinical Manifestations
Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...